Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
World J Cardiol ; 9(10): 787-793, 2017 Oct 26.
Artigo em Inglês | MEDLINE | ID: mdl-29104738

RESUMO

AIM: To determine whether the need for additional tricuspid valve repair is an independent risk factor when surgery is required for a left-sided heart disease. METHODS: One hundred and eighty patients (68 ± 12 years, 79 males) underwent tricuspid annuoplasty. Cox proportional-hazards regression model for multivariate analysis was performed for variables found significant in univariate analyses. RESULTS: Tricuspid regurgitation etiology was functional in 154 cases (86%), organic in 16 cases (9%), and mixed in 10 cases (6%), respectively. Postoperative mortality at 30 days was 11.7%. Mean follow-up was 51.7 mo with survival at 5 years of 73.5%. Risk factors for mortality were acute endocarditis [hazard ratio (HR) = 9.22 (95%CI: 2.87-29.62), P < 0.001], ischemic heart disease requiring myocardial revascularization [HR = 2.79 (1.26-6.20), P = 0.012], and aortic valve stenosis [HR = 2.6 (1.15-5.85), P = 0.021]. Significant predictive factors from univariate analyses were double-valve replacement combined with tricuspid annuloplasty [HR = 2.21 (1.11-4.39), P = 0.003] and preoperatively impaired ejection fraction [HR = 1.98 (1.04-3.92), P = 0.044]. However, successful mitral valve repair showed a protective effect [HR = 0.32 (0.10-0.98), P = 0.046]. Additionally, in instances where tricuspid regurgitation required the need for concomitant tricuspid valve repair, mortality predictor scores such as Euroscore 2 could be shortened to a simple Euroscore-tricuspid comprised of only 7 inputs. The explanation may lie in the fact that significant tricuspid regurgitation following left-sided heart disease represents an independent risk factor encompassing several other factors such as pulmonary arterial hypertension and dyspnea. CONCLUSION: Tricuspid annuloplasty should be used more often as a concomitant procedure in the presence of relevant tricuspid regurgitation, although it usually reveals an overly delayed correction of a left-sided heart disease.

2.
Thorac Cardiovasc Surg Rep ; 2(1): 38-9, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25360411

RESUMO

Extrapleural pneumonectomy (EPP) is indicated in selected group of patients with pleural mesothelioma. Diaphragmatic reconstruction represents a part of this complex operation. We present the case of a late diaphragmatic gastric herniation through prosthetic material after EPP.

3.
J Thorac Oncol ; 7(2): 386-9, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22139391

RESUMO

INTRODUCTION: We investigate the safety and efficacy of video-assisted mediastinoscopy (VAM) used for diagnosis of the superior vena cava syndrome. METHODS: In a 7-year period, we have done 447 VAM for malignant causes. We have compared, in a retrospective study from a prospectively maintained database, the differences between the groups with (first group) or without (second group) superior vena cava syndrome in terms of operative time, preoperative and postoperative complications, and results of pathologic examination. Statistical differences between the groups were calculated by χ2 test. RESULTS: Mean operative time for first (31 patients) and second (416 patients) groups was 18 and 34 minutes, respectively (p < 0.00). Mean hospital stay was 1.2 days in both the groups. Mortality rates for the first and second groups were 0 and 0.5% (p = 0.31); major morbidity rates were 0 and 0.7% (p = 0.50); and minor morbidity rates were 6.4 and 1.7% (p = 0.27), respectively. In the superior vena cava syndrome group, most of the lymph nodes biopsied were in paratracheal superior sites (81%); histology showed small cell lung cancer in 51.6%, non-small cell lung cancer in 25.8%, and lymphoma in 22.6%. CONCLUSIONS: VAM represents an important diagnostic tool in superior vena cava syndrome. Once decided to be used, we think that video technique is a good option with high rate of efficacy and low rates of mortality and morbidity.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/complicações , Neoplasias Pulmonares/complicações , Linfoma/complicações , Mediastinoscopia , Carcinoma de Pequenas Células do Pulmão/complicações , Síndrome da Veia Cava Superior/diagnóstico , Cirurgia Vídeoassistida , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Síndrome da Veia Cava Superior/etiologia , Síndrome da Veia Cava Superior/cirurgia , Adulto Jovem
4.
Ann Thorac Surg ; 94(3): 1010-1, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22916758
6.
J Thorac Oncol ; 4(10): 1236-41, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19641472

RESUMO

PURPOSE: Skeletal muscle metastases (SMM) from non-small cell lung cancer (NSCLC) are rarely encountered in clinical practice. The prognosis and the adequate treatment are not known. The aim of the study was to report our experience and to make an extensive literature research concerning SMM. PATIENTS AND METHODS: In our unit, we identified 16 patients with SMM in a 10-year period. The source of our literature search (English and French language) was the international MEDLINE database, and it exhausted all cited publications. RESULTS: We found 114 cases in the international literature (follow-up period mentioned in 72 cases). Pain was the most frequent symptom (83%). A mass was palpable in 78% of cases. The diagnosis was obtained by either fine needle/surgical biopsy or wide exeresis. The 5-year survival time was 11.5% with a median survival of 6 months. The 5-year survival rates: number of SMM - single versus multiple (13.6% [67 patients] versus 0% [21 patients]; p = 0.0022); disease-free interval (DFI) >6 months versus DFI < or =6 months (16.9% [18 patients] versus 9.1% [70 patients ]; p = 0.0458). We built three groups of prognostic significance: group I: DFI >6 months and single metastasis; group II: DFI >6 months or single metastasis; and group III: DFI < or =6 months and multiple metastasis. The 5-year survival rates were: group I (14 patients): group II (57 patients):group III (17 patients) = 28%:6%:0% (p = 0.0000), and the median survival was 19:9:4 months. CONCLUSION: The presence of SMM suggests an aggressive disease. Selection of patients for a local treatment is an important factor that determines survival. The ideal patient had a unique metachronous metastasic deposit that can be treated by surgery.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/secundário , Neoplasias Pulmonares/patologia , Neoplasias Musculares/secundário , Pneumonectomia , Adenocarcinoma/secundário , Adenocarcinoma/terapia , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Grandes/secundário , Carcinoma de Células Grandes/terapia , Carcinoma Pulmonar de Células não Pequenas/terapia , Carcinoma de Células Escamosas/secundário , Carcinoma de Células Escamosas/terapia , Terapia Combinada , Feminino , Humanos , Neoplasias Pulmonares/terapia , Masculino , Pessoa de Meia-Idade , Neoplasias Musculares/tratamento farmacológico , Estadiamento de Neoplasias , Dosagem Radioterapêutica , Taxa de Sobrevida , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA